Linezolid for treatment of vancomycin-resistant enterococcal peritonitis
A 42-year-old woman on continuous ambulatory peritoneal dialysis (CAPD) developed peritonitis secondary to vancomycin-resistant Enterococcus faecium and Candida albicans while hospitalized for pneumonia. She was treated successfully with intravenous linezolid, fluconazole given by nasogastric tube,...
Gespeichert in:
| Veröffentlicht in: | American journal of kidney diseases 2001-10, Vol.38 (4), p.E20-E20 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E20 |
|---|---|
| container_issue | 4 |
| container_start_page | E20 |
| container_title | American journal of kidney diseases |
| container_volume | 38 |
| creator | Bailey, E M Faber, M D Nafziger, D A |
| description | A 42-year-old woman on continuous ambulatory peritoneal dialysis (CAPD) developed peritonitis secondary to vancomycin-resistant Enterococcus faecium and Candida albicans while hospitalized for pneumonia. She was treated successfully with intravenous linezolid, fluconazole given by nasogastric tube, and removal of the peritoneal catheter. A concentration of linezolid above the minimum inhibitory concentration for most gram-positive pathogens, including vancomycin-resistant E faecium, was achieved in the dialysate fluid after an oral loading dose of 1200 mg. Additional data are needed to establish the role of linezolid in treating CAPD-associated peritonitis. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71206473</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71206473</sourcerecordid><originalsourceid>FETCH-LOGICAL-p207t-a5609d9dc903d3e8cee98d82a793cd0860e333adb4033cf581175dc842d7890c3</originalsourceid><addsrcrecordid>eNo1j01LxDAURYMgzjj6F6Qrd4WXvjYfSxnUEQqz0XXJJK8QaZuapML46y04ri6ce7hwr9iWNxWWQqHasNuUPgFAoxA3bMN5I4UGuWWH1k_0Ewbvij7EIkcyeaQpF6Evvs1kw3i2fiojJZ-yWfnaUQw2WGuGYqboc5h89umOXfdmSHR_yR37eHl-3x_K9vj6tn9qy7kCmUvTCNBOO6sBHZKyRFo5VRmp0TpQAggRjTvVgGj7RnEuG2dVXTmpNFjcsce_3TmGr4VS7kafLA2DmSgsqZO8AlFLXMWHi7icRnLdHP1o4rn7_46_tClVsA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71206473</pqid></control><display><type>article</type><title>Linezolid for treatment of vancomycin-resistant enterococcal peritonitis</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bailey, E M ; Faber, M D ; Nafziger, D A</creator><creatorcontrib>Bailey, E M ; Faber, M D ; Nafziger, D A</creatorcontrib><description>A 42-year-old woman on continuous ambulatory peritoneal dialysis (CAPD) developed peritonitis secondary to vancomycin-resistant Enterococcus faecium and Candida albicans while hospitalized for pneumonia. She was treated successfully with intravenous linezolid, fluconazole given by nasogastric tube, and removal of the peritoneal catheter. A concentration of linezolid above the minimum inhibitory concentration for most gram-positive pathogens, including vancomycin-resistant E faecium, was achieved in the dialysate fluid after an oral loading dose of 1200 mg. Additional data are needed to establish the role of linezolid in treating CAPD-associated peritonitis.</description><identifier>EISSN: 1523-6838</identifier><identifier>PMID: 11576907</identifier><language>eng</language><publisher>United States</publisher><subject>Acetamides - therapeutic use ; Adult ; Anti-Bacterial Agents - therapeutic use ; Enterococcus faecalis ; Female ; Gram-Positive Bacterial Infections - drug therapy ; Humans ; Kidney Failure, Chronic - therapy ; Linezolid ; Oxazolidinones - therapeutic use ; Peritoneal Dialysis, Continuous Ambulatory ; Peritonitis - drug therapy ; Peritonitis - microbiology ; Vancomycin Resistance</subject><ispartof>American journal of kidney diseases, 2001-10, Vol.38 (4), p.E20-E20</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11576907$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bailey, E M</creatorcontrib><creatorcontrib>Faber, M D</creatorcontrib><creatorcontrib>Nafziger, D A</creatorcontrib><title>Linezolid for treatment of vancomycin-resistant enterococcal peritonitis</title><title>American journal of kidney diseases</title><addtitle>Am J Kidney Dis</addtitle><description>A 42-year-old woman on continuous ambulatory peritoneal dialysis (CAPD) developed peritonitis secondary to vancomycin-resistant Enterococcus faecium and Candida albicans while hospitalized for pneumonia. She was treated successfully with intravenous linezolid, fluconazole given by nasogastric tube, and removal of the peritoneal catheter. A concentration of linezolid above the minimum inhibitory concentration for most gram-positive pathogens, including vancomycin-resistant E faecium, was achieved in the dialysate fluid after an oral loading dose of 1200 mg. Additional data are needed to establish the role of linezolid in treating CAPD-associated peritonitis.</description><subject>Acetamides - therapeutic use</subject><subject>Adult</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Enterococcus faecalis</subject><subject>Female</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Humans</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Linezolid</subject><subject>Oxazolidinones - therapeutic use</subject><subject>Peritoneal Dialysis, Continuous Ambulatory</subject><subject>Peritonitis - drug therapy</subject><subject>Peritonitis - microbiology</subject><subject>Vancomycin Resistance</subject><issn>1523-6838</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j01LxDAURYMgzjj6F6Qrd4WXvjYfSxnUEQqz0XXJJK8QaZuapML46y04ri6ce7hwr9iWNxWWQqHasNuUPgFAoxA3bMN5I4UGuWWH1k_0Ewbvij7EIkcyeaQpF6Evvs1kw3i2fiojJZ-yWfnaUQw2WGuGYqboc5h89umOXfdmSHR_yR37eHl-3x_K9vj6tn9qy7kCmUvTCNBOO6sBHZKyRFo5VRmp0TpQAggRjTvVgGj7RnEuG2dVXTmpNFjcsce_3TmGr4VS7kafLA2DmSgsqZO8AlFLXMWHi7icRnLdHP1o4rn7_46_tClVsA</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Bailey, E M</creator><creator>Faber, M D</creator><creator>Nafziger, D A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>Linezolid for treatment of vancomycin-resistant enterococcal peritonitis</title><author>Bailey, E M ; Faber, M D ; Nafziger, D A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p207t-a5609d9dc903d3e8cee98d82a793cd0860e333adb4033cf581175dc842d7890c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Acetamides - therapeutic use</topic><topic>Adult</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Enterococcus faecalis</topic><topic>Female</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Humans</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Linezolid</topic><topic>Oxazolidinones - therapeutic use</topic><topic>Peritoneal Dialysis, Continuous Ambulatory</topic><topic>Peritonitis - drug therapy</topic><topic>Peritonitis - microbiology</topic><topic>Vancomycin Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bailey, E M</creatorcontrib><creatorcontrib>Faber, M D</creatorcontrib><creatorcontrib>Nafziger, D A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of kidney diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bailey, E M</au><au>Faber, M D</au><au>Nafziger, D A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Linezolid for treatment of vancomycin-resistant enterococcal peritonitis</atitle><jtitle>American journal of kidney diseases</jtitle><addtitle>Am J Kidney Dis</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>38</volume><issue>4</issue><spage>E20</spage><epage>E20</epage><pages>E20-E20</pages><eissn>1523-6838</eissn><abstract>A 42-year-old woman on continuous ambulatory peritoneal dialysis (CAPD) developed peritonitis secondary to vancomycin-resistant Enterococcus faecium and Candida albicans while hospitalized for pneumonia. She was treated successfully with intravenous linezolid, fluconazole given by nasogastric tube, and removal of the peritoneal catheter. A concentration of linezolid above the minimum inhibitory concentration for most gram-positive pathogens, including vancomycin-resistant E faecium, was achieved in the dialysate fluid after an oral loading dose of 1200 mg. Additional data are needed to establish the role of linezolid in treating CAPD-associated peritonitis.</abstract><cop>United States</cop><pmid>11576907</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1523-6838 |
| ispartof | American journal of kidney diseases, 2001-10, Vol.38 (4), p.E20-E20 |
| issn | 1523-6838 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71206473 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acetamides - therapeutic use Adult Anti-Bacterial Agents - therapeutic use Enterococcus faecalis Female Gram-Positive Bacterial Infections - drug therapy Humans Kidney Failure, Chronic - therapy Linezolid Oxazolidinones - therapeutic use Peritoneal Dialysis, Continuous Ambulatory Peritonitis - drug therapy Peritonitis - microbiology Vancomycin Resistance |
| title | Linezolid for treatment of vancomycin-resistant enterococcal peritonitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T08%3A18%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Linezolid%20for%20treatment%20of%20vancomycin-resistant%20enterococcal%20peritonitis&rft.jtitle=American%20journal%20of%20kidney%20diseases&rft.au=Bailey,%20E%20M&rft.date=2001-10-01&rft.volume=38&rft.issue=4&rft.spage=E20&rft.epage=E20&rft.pages=E20-E20&rft.eissn=1523-6838&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71206473%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71206473&rft_id=info:pmid/11576907&rfr_iscdi=true |